Catalyst Pharmaceuticals Inc (CPRX)

11:34 AM

BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33 - marketscreener.com

11:34 AM

09:47 AM

Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from BofA to $34 | CPRX Stock News - GuruFocus

09:47 AM

Apr 17, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2025

Apr 15, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 15, 2025

Apr 11, 2025

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - Insider Monkey

Apr 11, 2025

Apr 11, 2025

11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey

Apr 11, 2025

Apr 09, 2025

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance

Apr 09, 2025

Apr 08, 2025

Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire

Apr 08, 2025

Apr 08, 2025

First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan

Apr 08, 2025

Apr 08, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - Quantisnow

Apr 08, 2025

Apr 08, 2025

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals - The Manila Times

Apr 08, 2025

Apr 02, 2025

What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN

Apr 02, 2025

Apr 02, 2025

Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Apr 02, 2025

Apr 01, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 01, 2025

Mar 31, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025

Mar 31, 2025

Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Mar 31, 2025

Mar 28, 2025

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN

Mar 27, 2025

Mar 26, 2025

Strong Revenue, Drug Performance Lift Catalyst Shares - FXEmpire

Mar 26, 2025

Mar 25, 2025

With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - simplywall.st

Mar 25, 2025

Mar 24, 2025

CPRX stock soars to all-time high of $24.8 amid robust growth - Investing.com

Mar 24, 2025

Mar 24, 2025

Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.

Mar 24, 2025

Mar 17, 2025

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance

Mar 17, 2025

Mar 14, 2025

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025

Mar 13, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 13, 2025

Mar 13, 2025

Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

Mar 13, 2025

Mar 12, 2025

Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Mar 12, 2025

Mar 11, 2025

Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

Mar 11, 2025

Mar 11, 2025

Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha

Mar 11, 2025

Mar 10, 2025

Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com

Mar 10, 2025

Mar 09, 2025

Gary Ingenito Sells 44,904 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - Defense World

Mar 09, 2025

Mar 08, 2025

Where are the Opportunities in (CPRX) - Stock Traders Daily

Mar 08, 2025

Mar 07, 2025

Catalyst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 07, 2025

Executive VP & Chief Commercial Officer Jeffrey Del Carmen Sold A Bunch Of Shares In Catalyst Pharmaceuticals - Simply Wall St

Mar 07, 2025

Mar 06, 2025

Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Mar 06, 2025

Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock - Investing.com India

Mar 06, 2025

Mar 05, 2025

Carmen Del Sells 30,423 Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus.com

Mar 05, 2025

Mar 05, 2025

Catalyst Pharmaceuticals chief compliance officer sells $1.45 million in stock - Investing.com

Mar 05, 2025

Mar 05, 2025

Catalyst Pharmaceuticals chief commercial officer sells $696,382 in stock By Investing.com - Investing.com South Africa

Mar 05, 2025